Abstract
Tumor necrosis factor-alpha inhibitor therapy for inflammatory bowel disease may be associated with paradoxical cutaneous adverse events, most commonly psoriasiform eruptions. We present the case of a pediatric female patient with Crohn's disease who developed multiple concurrent cutaneous eruptions while on infliximab treatment, including morphea, psoriasiform dermatitis, and genital lichen sclerosus. Although refractory to skin-directed treatments, all three conditions resolved upon discontinuation of infliximab, supporting their development as a paradoxical reaction to infliximab therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 519-522 |
Number of pages | 4 |
Journal | Pediatric Dermatology |
Volume | 40 |
Issue number | 3 |
DOIs | |
State | Published - May 1 2023 |
Keywords
- inflammatory bowel diseases
- infliximab
- lichen sclerosus et atrophicus
- localized
- scleroderma
- tumor necrosis factor inhibitors
ASJC Scopus subject areas
- Dermatology
- Pediatrics, Perinatology, and Child Health